The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Arrowhead Research's new formulation of dynamic polyconjugate (DPC) siRNA delivery system. The patent application No.13/032,029 covers claims for ...
Tags: siRNA delivery system, US Patent, dynamic polyconjugate, DPC platform
Hemispherx Biopharma has filed an amended NDA with ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica) for the use of Alferon N injection to treat Hepatitis C patients in Argentina. ANMAT has previously approved ...
Tags: Hemispherx Biopharma, Amended NDA, Alferon N Injection, ANMAT
GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients. Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C ...
Tags: FDA approval, thrombocytopenia therapy, chronic hepatitis C
US Food and Drug Administration (FDA) has approved an update to the labeling for Bristol-Myers Squibb's Baraclude to include data on African Americans and liver transplant recipients with chronic hepatitis B infection. The present ...
Ligand Pharmaceuticals partner GlaxoSmithKline has submitted regulatory applications in the US and European Union for the use of eltrombopag (Promacta/Revolade) to increase platelet counts in patients with hepatitis C. A supplemental ...
The FDA has granted fast track designation for Achillion Pharmaceuticals' ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV). ACH-3102 is a pan-genotypic second-generation NS5A inhibitor ...
Tags: FDA Fast Track Designation, chronic hepatitis C, pharmaceutical product